132eP Prognostic uncertainty in refractory mCRC: Evaluating outcomes with TAS-102 plus bevacizumab beyond traditional classification in a real-world setting
Paulo Frazão(Department of Public Health), Ana María Martins(Centro Hospitalar de Lisboa Ocidental), Thalita Silva Martins(Hospital Prof. Dr. Fernando Fonseca), Vitória Azevedo da Fonseca(Centro Hospitalar de Lisboa Ocidental), Margarida Lagarto(Centro Hospitalar de Lisboa Ocidental), Ana Rita Ferreira(Instituto Politécnico de Leiria), C.A.L.D.B. Monteiro(Centro Hospitalar Lisboa Norte), Inês Margarido(University of Lisbon), Maria Teresa Neves(Centro Hospitalar de Lisboa Ocidental), Teresa Duarte(Centro Hospitalar de Lisboa Ocidental), F. Verdasca(Administração Regional de Saúde de Lisboa e Vale do Tejo), Joana Luís(Lusíada University of Lisbon), S.B. de Almeida(Administração Regional de Saúde de Lisboa e Vale do Tejo), F. Ferraz de Liz(Administração Regional de Saúde de Lisboa e Vale do Tejo), T. Pina-Cabral(Centro Hospitalar de Lisboa Ocidental), J. Gramaça
Cited by 0
Related Papers
Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms of the Rectum: A Case Report
|Case Reports in Oncology|2024|4
Male Breast Cancer in Portugal: A Descriptive Analysis of a 20-Year Cohort
|European Journal of Breast Health|2025|2
P-191 Ampullary neoplasms – how to treat in real-world practice? A retrospective study
|Annals of Oncology|2022|0
P-351 Colon cancer in young patients – real-world data from a single center review
|Annals of Oncology|2023|0
Neoadjuvant cisplatin-based chemotherapy (NAC) in Muscle-invasive bladder cancer (MIBC): Real-world data
|European Urology Open Science|2023|0